Introduction
Rheumatoid arthritis (RA) is a multisystem autoimmune disease characterized by synovial inflammation, bony erosions and circulating autoantibodies. The disease likely is initiated by autoreactive CD4 þ T cells, recognizing a self-antigen, that leads to polyclonal B cell activation and the recruitment of inflammatory mediators and cells to the joints. Several genetic factors are known to confer susceptibility to the autoimmune process, including the expression of particular HLA-DR alleles. 1 In addition, several important inflammatory mediators, such as IL-1 and TNF-a, have been implicated in the perpetuation of the inflammatory state. 2, 3 A common feature of RA is the presence of autoantibodies, the best known of which is rheumatoid factor (RF). This antibody is directed towards the Fc portion of IgG and can be both of IgM and IgG isotypes. 4 The presence of IgG RF is associated with more severe extraarticular manifestations such as rheumatoid nodules and vasculitis. 5 RFs have been shown to activate complement, leading to the activation of neutrophils, the prominent cell type in synovial fluid. In RA, the role of RF/IgG immune complexes in the pathogenesis of the disease is not fully understood. They are likely to interact with FcgR on the surface of neutrophils, NK cells and monocyte/ macrophages. The binding of RF-containing immune complexes to FcgRII (CD32) on the surface of neutrophils leads to the production of cytokines and uptake of the immune complexes. 4, 5 Interestingly, RF has been shown to down-modulate the expression of FcgRIII (CD16) on NK cells and inhibit antibody-dependent cellular cytotoxicity (ADCC) on the one hand, but to stimulate the production of TNF-a and IFN-g from NK cells on the other. 6 These cells are all potent producers of inflammatory cytokines, and NK cells also appear to be important in the regulation of the inflammatory response.
Three highly homologous families of human FcgRs have been identified-FcgRI/CD64, FcgRII/CD32 and FcgRIII/CD16. 7 FcgRII (CD32) is the most widely expressed of the FcgR, being expressed on monocytes, neutrophils, B cells and NK cells. 8 There are three known genes that encode distinct FcgRII isoforms: FcgRIIA, FcgRIIB and FcgRIIC. These isoforms differ in their cellular expression, function and ligand binding specificity. FcgRIIa is predominantly expressed on monocytes and neutrophils. When it binds IgG, it signals the cell to increase phagocytosis and to secrete cytokines. 8 FcgRIIb is predominantly expressed on B cells. It has a negative regulatory role since it inhibits the activation of B cells via their antigen receptor. 8 We have recently found that FcgRIIc is predominantly expressed on NK cells and that it is able to trigger NK cell lysis of antibody-coated target cells and cytokine production. [9] [10] [11] Allelic polymorphisms of FcgR genes have been described 9, [12] [13] [14] [15] that affect the function of cells of the innate immune system including FcgRIIIA, 14, 16 FcgRIIA, 17 FcgRIIC, 7, 18 and FcgRIA. 19 In general, these polymorphisms have been shown to alter the ligand binding specificity of particular FcgR, such as FcgRIIa, 17 and FcgRIIIa. 14, 16 These allelic polymorphisms have proved to be clinically significant in infectious 20, 21 and autoimmune 12, 13, [22] [23] [24] diseases. The requirement for the expression of activating FcgR for disease manifestations has been demonstrated in several animal models of arthritis, including arthritis induced either by collagen 25 or immune complexes, 26, 27 and in the newly described animal model for RA, the K/BxN mouse. 28 In addition, mice deficient in the inhibitory FcgRIIb develop accelerated joint disease providing further evidence for the importance of FcgR in animal models of RA. 27 Since FcR þ cells, including macrophages, neutrophils and NK cells, are a prominent feature of rheumatoid synovium and synovial fluid, the binding of autoantibodies such as RF to these cells is likely to contribute to the inflammatory process in RA.
We have recently reported that around 40% of normal individuals express FcgRIIc (CD32) on their NK cells, in addition to FcgRIIIa (CD16). 9 This expression is due to an allelic polymorphism in the FcgRIIC gene 9 in which at amino acid 13 there is either a stop codon or a glutamine. 9 We have shown that both FcgRIIIa and FcgRIIc can trigger NK cell activation. 9, 10 Most recently, we have observed that a second allelic polymorphism allows expression of the inhibitory FcgRIIb instead of FcgRIIc on the NK cells of some individuals. 11 In the present study, we undertook a comprehensive analysis of FcgR allelic polymorphisms in patients with RA to determine whether these molecules are implicated in disease susceptibility and/or severity. We chose to focus our studies on FcgRIIA, FcgRIIC and FcgRIIIA because of their relevance to neutrophil (FcgRIIA) and NK cell (FcgRIIC and FcgRIIIA) function. These three FcgRs were examined both at the genetic and protein level in a large cohort of RA patients and normal donors. Significant associations between FcgRIIc expression on NK cells and FcgRIIC allelic polymorphisms and disease severity in RA patients were observed. These results suggest a role for FcgRs in the development of severe RA.
Results

Clinical features of RA patients in this study
The frequency of clinical features associated with disease severity in the RA patients is shown in Table 1 . The criteria were chosen such that patients with early aggressive disease could be identified. We hypothesized that FcgR polymorphisms would be more likely to affect the progression of the disease rather than being factors of disease susceptibility. The clinical criteria have been shown to predict early destructive disease 29, 30 and do not necessarily reflect the activity of the disease at the time of blood draw. Individuals were considered to have aggressive disease if they had 42 of the criteria listed in Table 1 and mild disease if they had 0 or 1 criteria. In all, 66 of the 148 patients were determined to have aggressive disease according to these criteria, whereas 11 were classified as having mild disease. The remaining 81 patients either could not be assigned due to lack of available information or had just two of the criteria. The frequency of RA patients with HLA-DR genotypes associated with RA is shown in Table 1 .
FccRIIA alleles are not associated with RA Neutrophils and macrophages are thought to play an important role in the pathogenesis of RA since they are prominent in the synovium and synovial fluid of RA patients and produce large amounts of inflammatory mediators. 31 FcgRIIa is constitutively expressed on the surface of neutrophils and macrophages, and the FcgRIIA gene has a single-nucleotide polymorphism (SNP) that results in either an arginine (R) or a histidine (H) being expressed at amino acid position 131. The polymorphism at amino acid 131, which changes the IgG binding specificity of FcgRIIA, has been implicated in both infectious and autoimmune diseases. 12, 13, 20, 21 Shown in Table 2 are the results of the FcgRIIA-131 genotyping from RA patients and normal controls. No differences in the frequency of FcgRIIA-131R or FcgRIIA-131H genotypes were observed between the normal donors and the RA subjects, which is consistent with previous reports. 32 Frequency of CD32 expression on NK cells from RA and normal individuals The expression of CD16 and CD32 on NK cells (CD56 pos ) from RA subjects and normal individuals was determined by two-color flow cytometry as described in the Methods. A representative two-color plot is shown in Figure 1 FccR expression on NK cells in rheumatoid arthritis AM Stewart-Akers et al CD32 negative (Figure 2b ). CD32 expression on NK cells was detected with the anti-CD32 mAb KB61, but was negative when analyzed using the anti-CD32 mAbs IV.3 or AT10, consistent with the antibody staining pattern, we previously reported to be characteristic of human NK cells. 9, 11 Of the 133 RA patients who were analyzed in this way, 56 (43%) expressed CD32 on their NK cells compared to 43/95 (45%) normal donors. Thus, similar proportions of RA patients and normal donors express CD32 on their NK cells.
Levels of expression of CD16 and CD32 are reduced on NK cells from RA patients However, when we examined the levels of CD32 and CD16 expression, we found differences between RA subjects and healthy controls. Specifically, we observed a significant reduction in the level of CD32 expression, as determined by mean fluorescence intensity (MFI), on NK cells from RA subjects compared to those from normal donors (Po0.0001, Figure 3a ). NK cells from normal donors could be divided into high and low CD32 expressors (Figure 3a ), but all RA subjects fell into the low expressing group. The level of CD32 expression in normal donors was consistent over time. 11 Samples from three RA subjects were obtained at multiple time points, and the CD32 expression levels likewise were consistently low.
All donors expressed CD16 on the surface of NK cells (Figures 1 and 2 ). Interestingly, the expression level of CD16 was significantly decreased in RA subjects (MFI ¼ 148; 95% CI 114-184) compared to normal donors (MFI ¼ 209; 95% CI 231-349) (Figure 3b , Po0.01). It has been reported previously that the presence of RF and the generation of immune complexes could play a role in the downregulation of FcgR expression on NK cells. 6 RA subjects compared to normal donors (Po0.001). Lastly, when the NK cells were stained with an antibody to determine the amount of human IgG bound to the cell surface, this was similar between normal donors and RA subjects (Figure 3d ). This suggests that IgG-containing immune complexes bound to the NK cells in RA patients were not blocking the binding of either the anti-CD32 or anti-CD16 mAbs, and that the decrease in MFI observed in RA patients indicated a real decrease in the surface expression of these molecules. The reduction in CD16 expression might be correlated with the recent description of significant levels of soluble CD16 in the serum of RA patients. 33 Abnormal distribution of FccRIIC alleles in RA patients We next carried out molecular analysis of the CD32 isoforms expressed by RA patients and normal donors. An allelic polymorphism in the FcgRIIC gene at amino acid 13 (FcgRIIC-13), which falls in the first extracellular domain, determines the presence or absence of CD32 on NK cells. 9 A SNP converts a glutamine (FcgRIIC-13Q) to a stop codon (FcgRIIC-13ST), thereby creating a null allele. We have developed a nested PCR-based allelespecific restriction analysis, which allows us to identify homozygotes/heterozygotes for the FcgRIIC-13ST containing allele. 34 All CD32
neg RA subjects and normal donors were found to be homozygous for FcgRIIC-13ST allele (Table 3) . Thus, the lack of CD32 expression on NK cells was correlated with FcgRIIC-13ST allele homozygosity as in previous studies. 9, 11 In the case of the CD32 pos individuals, we have previously identified two major molecular patterns. 11 In 52% of normal donors, the CD32 expression could be attributed to the presence of the FcgRIIC-13Q allele, and these individuals were homozygous or heterozygous for the FcgRIIC-13Q allele. The remaining CD32 pos individuals were found to be homozygous for the FcgRIIC-13ST allele. We previously have shown that individuals with this molecular pattern appear to express the inhibitory FcgRIIb isoform. The molecular analysis of CD32 pos RA subjects revealed that only 29% (8/28) apparently express the FcgRIIC-13Q allele, while 71% were homozygous for the FcgRIIC-13ST allele (Table 3 ). These results suggest that the frequency of RA subjects that express FcgRIIc on their NK cells is lower compared to normal donors, and that a higher percentage could express the inhibitory FcgRIIb isoform.
FccRIIC alleles are associated with disease severity in RA patients These results led us to speculate whether the expression of CD32 was in any way correlated with disease severity in the RA patients. Thus, we determined the proportion of RA patients who could be classified as having an aggressive form of the disease in both the CD32 pos and CD32 neg groups. This classification was based on previous studies that had identified clinical features associated with rapid progression to erosive disease. 29, 30 These included early age at onset, RF and high ESR at the time of diagnosis and the presence of two HLA shared epitope alleles. In addition, we included the criteria of erosions during the first year since diagnosis and the presence of extra-articular disease. Interestingly, 65% (43/66) of RA patients with two or more of these criteria disease were CD32 neg as determined by flow cytometric analysis, whereas only 30% of RA patients with mild disease were CD32 neg (Table 4) : this difference was statistically significant (P ¼ 0.04). These results suggest that allelic polymorphisms at the FcgRIIC locus influence disease severity in RA.
FccRIIIA allelic polymorphisms in RA
A relevant allelic polymorphism of the FcgRIIIA (CD16) gene is a SNP at amino acid position 176 in the EC2 domain, which results in the change of the phenylalanine (F) at this position to valine (V). This polymorphism has functional significance since NK cells from V/V homozygous bind much higher levels of both IgG1 and IgG3 than those from F/F homozygous individuals. 15 We determined the frequencies of the FcgRIIIA-176V and FcgRIIIA-176F alleles in populations of RA patients and normal donors. When considered as a whole, no significant differences in the frequency of FcgRIIIA alleles were observed between RA subjects and normal donors (Table 5 ). However, statistically significant differences in the genotype frequencies were observed when the groups were compared based on CD32 expression. The presence of the FcgRIIIA-176F/F genotype was over-represented in the CD32 neg compared to CD32 pos subjects; this was statistically significant for RA patients (P ¼ 0.0002) but not for normal donors (P ¼ 0.09). The frequency of the FcgRIIIA-176F allele was 0.73 in CD32 neg RA patients, whereas it was 0.58 in CD32 pos RA patients. A similar difference was observed for CD32 proximity to one other in the genome. 35 Thus, RA patients who have severe disease have a higher probability of lacking CD32 expression on their NK cells and this is frequently coupled with a FcgRIIIA (F) allele that binds IgG poorly.
Discussion
In this study, we have performed a comprehensive analysis of the expression pattern and allelic polymorphisms of three FcgR genes (FcgRIIA, FcgRIIC and FcgRIIIA) in a large sample of RA patients. We have found that the level of FcgR (CD16 and CD32) expression on NK cells is lower in RA patients than in normal individuals. Those RA patients who do not express CD32 on their NK cells have more severe disease. Genotypic analysis suggested that the CD32 isoform expressed by the majority of RA patients was the inhibitory FcgRIIb isoform, rather than the activating FcgRIIc1 isoform. This conclusion is based on the higher frequency of individuals who typed FcgRIIC-13ST/ST, coupled with a flow cytometric staining pattern for CD32 characteristic of FcgRIIc/b. 11 Furthermore, in both RA patients and normal donors, there was a higher frequency of the FcgRIIIA-176F allele in individuals lacking CD32 expression on their NK cells. The FcgRIIIA-176F allele binds IgG poorly and thus the combination of this allele with a lack of CD32 expression in NK cells was characteristic of RA subjects with severe disease. Since FcgRIIC and FcgRIIIA are predominantly expressed by NK cells, these 36 and RF can stimulate cytokine release from these cells. 37 More recently, the synovial tissue expression of IL-15 was observed. 38 This cytokine induced TNF-a production by synovial fluid T cells. 39 IL-15 is also a potent activator of NK cell function, stimulating proliferation, cytokine secretion and cytotoxicity. 40 In addition, recent data suggest that the action of certain drugs effective in the treatment of RA (antimalarials and cyclosporin A) could be attributable to effects on NK cell activation. 41 In contrast to the potentially proinflammatory role that NK cells might play in RA, these cells could also function in a regulatory fashion. Activation of NK cells via CD2 results in the production of TGF-b, which in turn induces suppressive CD8 cells that inhibit antibody production. 42 In addition, the recent identification of MICA, a ligand for the receptor NKG2D expressed on NK cells and gd T cells, as a marker of protection from RA implies a role for NK cells in this disease. 43 The fact that MICA is inducibly expressed on monocytes and DC suggests that the interaction between DC/monocytes with NK cells may be relevant to RA pathogenesis. Recently, the stimulatory KIR2DS2 receptor expressed on NK cells and a population of CD4 þ T cells also was recognized as a genetic risk factor influencing the pattern of RA disease expression. 43 The anti-CD32 antibody staining pattern (KB61 pos but AT-10 low and IV.3 neg ) observed in the RA patients studied here was shown in earlier studies by our laboratory to indicate the presence of the FcgRIIC-13Q allele. 9 We subsequently showed that this antibody-staining pattern was also seen in individuals who expressed FcgRIIb on their NK cells due to the fact the mAb AT10 is sensitive to a polymorphism at FcgRIIB-161Y/F. 11 Most individuals appear to have the FcgRIIB-161Y polymorphism, which is poorly seen by the AT10 mAb. When the RA subjects were molecularly typed by RT-PCR for the FcgRIIC-13 polymorphism, the majority was homozygous for FcgRIIC-13ST. This antibody staining pattern in conjunction with the molecular genotype suggest that the FcgRIIb and not the FcgRIIc isoform is the one expressed by NK cells from RA patients. 11 Functional analysis of NK cells from an individual with this molecular pattern demonstrated both a lack of rADCC stimulated via anti-CD32 mAbs and reduced ADCC, consistent with the ITIM present in the FcRIIb isoform. 11 The presence of the inhibitory FcgRIIb on the NK cells of some RA patients may modulate the activatory functions of other NK cell receptors, such as CD16, and this is under further investigation. Thus, the levels of FcgR expression, as well as the actual isoform expressed on NK cells, may be important in determining susceptibility to rheumatoid arthritis.
Many cells express FcgRs, including monocytes/ macrophages, dendritic cells (DC) and neutrophils. All of these cell types play an important role in the pathogenesis of RA. Some of the associations that we report here may exert their influence through the function of these cells. Patients with RA have an increase in the frequency of CD14 þ CD16 þ monocytes in the synovium and peripheral blood; 44 this was associated with increased TNF-a production following exposure to aggregated IgG. 44, 45 DC are known to play an important role in the initiation of the immune response. Abnormalities in DC phenotype and function have been reported in RA. 46, 47 DC precursors readily migrate into the rheumatoid synovial tissue where they can undergo maturation. 47, 48 Recent studies demonstrated that the culture of monocytes with cytokines found in RA synovial fluid led to the generation of a DC subset with strong Th1 stimulatory capacity. 49 Interestingly, a CD16 þ DC subset with an increased capacity to secrete inflammatory cytokines has been identified. 50 Thus, it is possible that polymorphisms in the CD16 (FcgRIIIA) gene could affect DC function and phenotype.
These results suggest that polymorphisms in FcgRIIIA (CD16) and FcgRIIC/B (CD32) genes may be correlated with disease severity in RA patients. They do not appear to be disease susceptibility genes, but rather modify the disease expression in RA patients. The present studies were focused on the expression of CD16 and CD32 on NK cells, but other cells such as monocyte/macrophages and DC also express these molecules. Future studies will examine the functional consequences of FcgRIIIA (CD16) and FcgRIIC/B (CD32) polymorphisms for NK cells, macrophages and DC. The different combinations of activatory and inhibitory receptors on the surface of cells of the innate immune system are likely to influence the pattern of disease expression in RA.
Methods
Patients and controls
Between 2000 and 2002, 148 RA subjects were recruited for the current study from persons receiving arthritis care at the University Arthritis Center. All RA subjects met the American Rheumatism Association 1987 criteria for RA, 51 had disease duration for X2 years, and gave informed consent prior to their participation in this study, which was approved by the University of Pittsburgh IRB. RA disease activity and severity were assessed by direct examination of each patient and review of the medical record for criteria of disease severity, as indicated by the following: (1) presence of serum RF (ever); (2) joint erosions within the first year of disease; (3) presence of extra-articular disease; (4) presence of two shared epitope alleles; (5) ESR 433 mm/h at presentation; and (6) age o45 at diagnosis. Severe rheumatoid arthritis was defined as the presence of 42 of the six criteria listed above at recruitment, whereas those patients with o2 criteria were considered to have mild disease. These criteria were selected based on clinically useful predictors of disease progression. 29, 30 A list of medications used at the time of phlebotomy was also obtained.
RA has been shown to be associated with a group of HLA-DRB1 alleles that all share a common epitope (SE). 1 These alleles include DRB1*0401, 0404, 0405, 0408, 0101, 0102, 1001, and 1402. All individuals in the study were HLA typed using DNA typing technology as previously described. 52 PCR amplification of the DRB1 chain genes was performed and the typing carried out using digoxigenin-labeled probes as described. 52 Patients were classified as having 0, 1 or 2 SE based on the presence of these alleles, as determined by DNA typing.
Normal donors (38 females, 42 males and 25 of unknown gender, n ¼ 105) were recruited from peers who did not have RA, from which informed consent was obtained, or from deidentified Central Blood Bank (Pittsburgh, PA) donors.
Cell isolation and flow cytometry
At the time of a clinic visit, 20 ml of heparinized blood was obtained. Peripheral blood mononuclear cells (PBMC) were isolated by separation on Histopaque-1077 (Sigma Diagnostics, St Louis, MO, USA). Some of the PBMC were used to perform a two-color flow cytometric analysis in order to determine the levels of FcR expression on NK cells.
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CD32 and CD16 expression was determined by direct immunofluorescence using the available panel of FITCconjugated anti-CD32 mAbs (clone KB61, DAKO Corporation, Carpinteria, CA, USA; clone IV.3, Mederex, Annadale, NJ, USA and clone AT-10, Serotec Inc., Raleigh, NC, USA) and anti-CD16-FITC (Mederex) mAbs. The NK cell population was identified by incubation with PE-conjugated anti-CD56 (Pharmingen, San Diego, CA, USA). In addition, the presence of human IgG on the surface of NK cells was determined using FITC-conjugated anti-Human IgG (Caltag Laboratories, Burlingame, CA, USA). Negative controls included incubation with the relevant isotype control antibodies. As an additional precaution to prevent nonspecific mAb binding to NK cells, we coincubated the cells with human IgG (50 mg/ml) as a competitor to prevent the binding of the mAbs by their Fc region.
The samples were then run on a Coulter XL FACS machine. At least 50 000 events were collected. Lymphocytes were gated by FSC and SSC characteristics. The NK cells were identified by gating for CD56 þ cells; the remaining markers were analyzed only on the gated NK cells. The data were analyzed using the scientific data analysis software from FlowJo (Tree Star, Inc., San Carlos, CA, USA) to determine the levels of expression of various cell surface markers on NK cells.
Typing for FccRIIA and FccRIIIA polymorphisms Genomic DNA was isolated from PBMC using the Qiagen DNA isolation kit according to the manufacturer's protocol. The allelic polymorphism of the FcgRIIIA gene at position 176 was examined using a previously described nested PCR-based allele-specific restriction analysis technique. 53 The allelic polymorphism of the FcgRIIA gene at position 131 was performed as described. 54 These protocols 53, 54 allowed for a clear discrimination between homozygous and heterozygous individuals for the FcgRIIIA and FcgRIIA polymorphisms.
Analysis of FccRIIC polymorphisms by RT-PCR
We have previously shown that the expression of CD32 on NK cells is determined by an allelic polymorphism of the FcgRIIC gene 9 at amino acid 13 in the first extracellular domain (FcgRIIC-13). A single-nucleotide change converts a glutamine (FcgRIIC-13 gln ) to a stop codon (FcgRIIC-13 stop ), thereby creating a null allele. We have recently developed a nested PCR-based allelespecific restriction analysis method that allowed us to identify homozygotes/heterozygotes for the FcgRIIC-13 allelic polymorphism. 34 
Statistics
The differences in MFI of FcgRIII between RA patients and normal donors were assessed using one-way ANOVA analysis with Dunn's post-test. The differences in MFI of FcgRII and the MFI of total antibody bound between the two populations were assessed using unpaired t-test with Welch's correction. Differences in FcgRIIA and FcgRIIIA genotype frequencies between patients and normal donors were assessed using a w 2 -analysis. All analyses were performed using GraphPad Prism version 3.0a for Macintosh (GraphPad Software, San Diego, CA, USA).
